Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group

Nomoto, Yasuo; Kawaguchi, Yoshindo; Kubo, Hitoshi; Honda, Hiroshi; Sakai, Shinji; Kurokawa, Kiyoshi

doi:10.1016/s0272-6386(96)90501-6

Cited by 218 publications

(264 citation statements)

References 17 publications

Supporting

Mentioning

253

Contrasting

Unclassified

Order By: Relevance

“…The rate of EPS among patients on PD was 1.5%, with an incidence of 4.9 per 1,000 person-years. This rate is well within those reported previously (0.7-3.3%) [2][3][4][5][6][7]. Interestingly, the EPS rate increased with longer duration of PD up to 5 years (from 0% at\1 year to 8.8% at[5 to 6 years), and then decreased (5% at[6 years).…”

supporting

confidence: 91%

“…Thus, the number of EPS cases diagnosed before stopping PD seems to be decreasing [1][2][3][4][5][6][7]. During last few years, new biocompatible PD solutions are being used more widely and it is possible that such increased use may be responsible for a decrease in the incidence of EPS diagnosed during PD.…”

Section: Exploring Ways To Prevent Epsmentioning

confidence: 99%

“…Furthermore, two previous publications [6,7] also suggested that PD duration should not exceed 5 years in order to decrease the risk of EPS, irrespective of whether patients were awaiting a kidney transplant.…”

mentioning

confidence: 99%

“…Thus the incidence of EPS increases with the duration of PD but after about 5 years this increase seems to be lower [1][2][3][4][5][6][7]. The Scottish Renal Registry study [1], that produced the best published data on the association between length of PD and EPS, showed a decrease in the rate of EPS development after 6 years of PD.…”

mentioning

confidence: 99%

See 3 more Smart Citations

No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis

Garosi

Oreopoulos

2009

Int Urol Nephrol

View full text Add to dashboard Cite

Encapsulating peritoneal sclerosis (EPS) is drawing attention to the PD community because of its unpredictable onset and high mortality.Recently, the Scottish Renal Registry [1] has established the incidence of EPS and its correlation with PD duration in that region. The rate of EPS among patients on PD was 1.5%, with an incidence of 4.9 per 1,000 person-years. This rate is well within those reported previously (0.7-3.3%) [2][3][4][5][6][7]. Interestingly, the EPS rate increased with longer duration of PD up to 5 years (from 0% at\1 year to 8.8% at[5 to 6 years), and then decreased (5% at[6 years). The median duration of PD before EPS developed was 5.1 years. At the time of diagnosis only 26% of patients with EPS were on PD. In the remainder (74%), EPS was diagnosed after PD had been discontinued; 50% of them were diagnosed with EPS after kidney transplantation with calcineurin inhibitor-based immunosuppression.

show abstract

supporting

confidence: 91%

Section: Exploring Ways To Prevent Epsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis

Garosi

Oreopoulos

2009

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

“…The diagnosis of the disease is usually made at laparotomy, but findings on CT scans and ultrasounds of the peritoneum have been used to support diagnoses. [1][2][3] We report an anti-HCV-positive case of SEP, presenting with severe abdominal symptoms, malnutrition ascites, and blood-stained dialysate. A 33-year-old man developed end-stage renal disease secondary to unknown origin ten years ago.…”

mentioning

confidence: 99%

Sclerosing Encapsulating Peritonitis in an Anti-HCV-Positive Patient on Chronic Ambulatory Peritoneal Dialysis

et al. 2007

View full text Add to dashboard Cite

The future of peritoneal dialysis: PD in 2010 and beyond

Burkart

2010

Dialysis & Transplantation

View full text Add to dashboard Cite

Peritoneal dialysis (PD) has been used to treat patients with stage V chronic kidney disease since 1976. The number of patients on PD varies from country to country and was only about 8% of the U.S. population by the end of 2009, despite the fact that medical outcome data would seem to favor more utilization of PD. For instance, data from the United States Renal Data Systems suggests that the relative risk of death for patients on PD versus center hemodialysis (CHD) has been improving, tending to favor those on PD for longer periods of time. In addition, infectious complications have been markedly reduced. In these economic times it is important to note that PD is less costly than CHD, which has influenced anticipated changes in government reimbursement—such as the bundling of dialysis‐related services in the U.S. These facts should stimulate a renewed interest in home therapies, especially PD. However, for this therapy to be more successful, the PD community must better educate its members (in the U.S., PD education during fellowship is often lacking, many current PD units are small and the number of well‐trained PD nurses may not be able to optimally meet an increase in demand). Peritoneal dialysis will face many challenges, such as: frequent hemodialysis schedules that may be more and more appealing to patients and providers; the aging of the end‐stage renal disease (ESRD) population; regulatory issues; lack of infrastructure at some units; and problems related to long‐term use of PD. This article will review some of these challenges.

show abstract

Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group

Cited by 218 publications

References 17 publications

No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis

No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis

Sclerosing Encapsulating Peritonitis in an Anti-HCV-Positive Patient on Chronic Ambulatory Peritoneal Dialysis

The future of peritoneal dialysis: PD in 2010 and beyond

Contact Info

Product

Resources

About